DK4011908T5 - Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf - Google Patents

Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK4011908T5
DK4011908T5 DK21207279.7T DK21207279T DK4011908T5 DK 4011908 T5 DK4011908 T5 DK 4011908T5 DK 21207279 T DK21207279 T DK 21207279T DK 4011908 T5 DK4011908 T5 DK 4011908T5
Authority
DK
Denmark
Prior art keywords
ultra
methods
long
fusion proteins
acting insulin
Prior art date
Application number
DK21207279.7T
Other languages
English (en)
Other versions
DK4011908T3 (da
Inventor
Thomas M Lancaster
Todd C Zion
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of DK4011908T3 publication Critical patent/DK4011908T3/da
Application granted granted Critical
Publication of DK4011908T5 publication Critical patent/DK4011908T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
DK21207279.7T 2018-06-29 2019-06-28 Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf DK4011908T5 (da)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201862692507P 2018-06-29 2018-06-29
US201862692498P 2018-06-29 2018-06-29
US201862693814P 2018-07-03 2018-07-03
US201862696645P 2018-07-11 2018-07-11
US201862698648P 2018-07-16 2018-07-16
US201862702167P 2018-07-23 2018-07-23
US201862719347P 2018-08-17 2018-08-17
US201862740735P 2018-10-03 2018-10-03
US201862743358P 2018-10-09 2018-10-09
US201862774682P 2018-12-03 2018-12-03
US201862781378P 2018-12-18 2018-12-18
US201862781368P 2018-12-18 2018-12-18
US201962824176P 2019-03-26 2019-03-26
US201962827809P 2019-04-01 2019-04-01
US201962837188P 2019-04-22 2019-04-22
EP19826154.7A EP3655006B1 (en) 2018-06-29 2019-06-28 Ultra-long acting insulin-fc fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
DK4011908T3 DK4011908T3 (da) 2023-08-07
DK4011908T5 true DK4011908T5 (da) 2024-08-12

Family

ID=68985236

Family Applications (4)

Application Number Title Priority Date Filing Date
DK21207279.7T DK4011908T5 (da) 2018-06-29 2019-06-28 Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK21164434.9T DK3892628T3 (da) 2018-06-29 2019-06-28 Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
DK19826154.7T DK3655006T3 (da) 2018-06-29 2019-06-28 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK22203969.5T DK4186920T5 (da) 2018-06-29 2019-06-28 Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK21164434.9T DK3892628T3 (da) 2018-06-29 2019-06-28 Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
DK19826154.7T DK3655006T3 (da) 2018-06-29 2019-06-28 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK22203969.5T DK4186920T5 (da) 2018-06-29 2019-06-28 Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse

Country Status (15)

Country Link
US (9) US10961294B2 (da)
EP (5) EP3655006B1 (da)
JP (2) JP7417277B2 (da)
KR (2) KR20210029210A (da)
CN (2) CN120665204A (da)
AU (2) AU2019291945B2 (da)
BR (1) BR112020026777A2 (da)
CA (1) CA3104144A1 (da)
DK (4) DK4011908T5 (da)
FI (2) FI4011908T3 (da)
HR (4) HRP20220091T1 (da)
HU (4) HUE060471T2 (da)
LT (4) LT3892628T (da)
SI (4) SI4186920T1 (da)
WO (1) WO2020006529A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
TW202237174A (zh) * 2020-12-14 2022-10-01 美商美國禮來大藥廠 治療糖尿病之方法
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
WO2023064711A2 (en) * 2021-10-14 2023-04-20 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI871539B (zh) 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
KR20240158331A (ko) * 2022-03-16 2024-11-04 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체, 이의 융합 단백질 및 의약적 용도
JP2025522529A (ja) * 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
US12454565B2 (en) * 2024-03-21 2025-10-28 Akston Biosciences Corporation PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026030590A1 (en) 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026030596A1 (en) 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026030592A1 (en) 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
US20260035415A1 (en) 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026039359A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039341A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039340A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026085182A1 (en) 2024-10-16 2026-04-23 Akston Biosciences Corporation Ngf analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026085180A2 (en) 2024-10-16 2026-04-23 Akston Biosciences Corporation Ngf analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026085175A1 (en) 2024-10-16 2026-04-23 Akston Biosciences Corporation Ngf analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026085185A2 (en) 2024-10-16 2026-04-23 Akston Biosciences Corporation Ngf analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026085178A1 (en) 2024-10-16 2026-04-23 Akston Biosciences Corporation Ngf analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US7169894B2 (en) * 2001-11-14 2007-01-30 Mirari Biosciences, Inc. Methods and compositions for reverse translation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20100143479A1 (en) 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
US20140302028A1 (en) 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
EP2885543B1 (en) * 2012-08-17 2019-01-16 Dresser-Rand Company System and method for detecting stall or surge in radial compressors
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
DK2963056T3 (da) 2013-02-26 2020-02-17 Hanmi Pharm Ind Co Ltd Insulinanalog og anvendelse deraf
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
BR112017004544A2 (pt) 2014-10-06 2018-01-23 Univ Case Western Reserve insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus
WO2016064606A1 (en) 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
KR20170106373A (ko) 2015-01-20 2017-09-20 케이스 웨스턴 리저브 유니버시티 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체
WO2016119023A1 (en) * 2015-01-29 2016-08-04 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
EP3260139A4 (en) 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
ES2754432T3 (es) * 2015-05-04 2020-04-17 Apogenix Ag Proteínas agonistas de receptor CD40 de cadena sencilla
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
CN114835793A (zh) 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
WO2018014091A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP7158378B2 (ja) * 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
US20200181258A1 (en) 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
UY37629A (es) 2017-03-07 2018-10-31 Univ Case Western Reserve Análogos de insulina de cadena simple estabilizados por un cuarto puente disulfuro
US10572594B2 (en) 2017-08-01 2020-02-25 Intuit Inc. Extracting domain-specific actions and entities in natural language commands recognized based on edition and recognition scores
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2020069011A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
WO2020070276A1 (en) 2018-10-05 2020-04-09 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and egf(a) peptides
CN113330025A (zh) 2018-11-19 2021-08-31 卡斯西部储备大学 具有聚丙氨酸c结构域子区段的单链胰岛素类似物
CA3139946A1 (en) 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Also Published As

Publication number Publication date
CN120665204A (zh) 2025-09-19
US20220009990A1 (en) 2022-01-13
EP4011908A1 (en) 2022-06-15
LT4186920T (lt) 2024-04-25
DK4011908T3 (da) 2023-08-07
US20250289863A1 (en) 2025-09-18
EP3655006A1 (en) 2020-05-27
US20200157169A1 (en) 2020-05-21
EP3655006B1 (en) 2021-11-17
US20200157170A1 (en) 2020-05-21
DK3892628T3 (da) 2022-11-14
US10961294B2 (en) 2021-03-30
EP3655006A4 (en) 2021-01-13
DK4186920T3 (da) 2024-03-25
EP3892628B1 (en) 2022-09-07
AU2024287186A1 (en) 2025-01-23
LT4011908T (lt) 2023-09-11
EP4011908B1 (en) 2023-06-07
HRP20230991T1 (hr) 2023-12-08
EP4344738A3 (en) 2024-05-22
EP4186920A1 (en) 2023-05-31
HUE065725T2 (hu) 2024-06-28
FI4186920T3 (fi) 2024-03-20
SI4186920T1 (sl) 2024-05-31
KR20250139414A (ko) 2025-09-23
SI4011908T1 (sl) 2023-10-30
AU2019291945B2 (en) 2024-11-14
DK3655006T3 (da) 2022-02-21
HRP20220091T1 (hr) 2022-04-15
HUE062719T2 (hu) 2023-11-28
CN113038964B (zh) 2025-05-27
EP4344738A2 (en) 2024-04-03
US10947292B2 (en) 2021-03-16
US20200407413A1 (en) 2020-12-31
AU2019291945A1 (en) 2021-01-14
HUE060471T2 (hu) 2023-03-28
HUE058005T2 (hu) 2022-06-28
WO2020006529A1 (en) 2020-01-02
US10851147B2 (en) 2020-12-01
JP2024045117A (ja) 2024-04-02
US10870686B2 (en) 2020-12-22
US20200231646A1 (en) 2020-07-23
EP3892628A1 (en) 2021-10-13
SI3892628T1 (sl) 2023-01-31
HRP20240408T1 (hr) 2024-06-07
US20200157171A1 (en) 2020-05-21
JP2021530210A (ja) 2021-11-11
HRP20221418T1 (hr) 2023-01-06
US11673934B2 (en) 2023-06-13
US20220017590A1 (en) 2022-01-20
LT3655006T (lt) 2022-03-10
CN113038964A (zh) 2021-06-25
US11261229B2 (en) 2022-03-01
BR112020026777A2 (pt) 2021-03-30
LT3892628T (lt) 2022-12-12
CA3104144A1 (en) 2020-01-02
US20240101635A1 (en) 2024-03-28
DK4186920T5 (da) 2024-07-22
JP7417277B2 (ja) 2024-01-18
EP4186920B1 (en) 2024-01-03
US11773151B2 (en) 2023-10-03
KR20210029210A (ko) 2021-03-15
JP7510728B2 (ja) 2024-07-04
FI4011908T3 (fi) 2023-08-04
SI3655006T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
DK4011908T5 (da) Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK4232463T3 (da) Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL281683A (en) Dll3 binding proteins and methods of use
IL281783A (en) Sirpα binding proteins and methods of use thereof
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
IL288373A (en) flt3l-fc fusion proteins and methods of use
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
IL275742A (en) IL-22 FC fusion proteins and methods of use
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK4190355T3 (da) Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3177307T3 (da) Interleukin-2/interleukin-2 receptor-alpha-fusionsproteiner og fremgangsmåder til anvendelse
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it